PMID- 36865740
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230304
IS  - 1741-427X (Print)
IS  - 1741-4288 (Electronic)
IS  - 1741-427X (Linking)
VI  - 2023
DP  - 2023
TI  - Clinical Efficacy of Huangkui Capsule Plus Methylprednisolone for Immunoglobulin 
      A Nephropathy and Its Effect on Renal Function and Serum Inflammatory Factors.
PG  - 3020033
LID - 10.1155/2023/3020033 [doi]
LID - 3020033
AB  - OBJECTIVE: To assess the clinical efficacy of Huangkui capsule plus 
      methylprednisolone for immunoglobulin A (IgA) nephropathy and its effect on renal 
      function and serum inflammatory factors. METHODS: A total of 80 patients with IgA 
      nephropathy admitted to our hospital from April 2019 to December 2021 were 
      recruited and assigned (1 : 1) to receive either conventional 
      drugs + methylprednisolone tablets (observation group) or conventional 
      drugs + methylprednisolone tablets + Huangkui capsules (experimental group), with 
      40 patients in each group. Outcome measures included clinical efficacy, renal 
      function indices, serum inflammatory factor levels, and adverse events. RESULTS: 
      The experimental group showed a significantly higher clinical efficacy versus the 
      observation group (P < 0.05). Patients in the experimental group had 
      significantly lower serum creatinine, serum urea nitrogen, fibrinogen, and 24 h 
      urine protein levels than those in the observation group after treatment (P < 
      0.05). After treatment, the experimental group showed lower levels of tumor 
      necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), and monocyte chemoattractant 
      protein-1 (MCP-1) than the observation group (P < 0.05). The differences in the 
      adverse events between the two groups did not come up to the statistical standard 
      (P > 0.05). CONCLUSION: Huangkui capsule + methylprednisolone provides a feasible 
      therapeutic option for IgA nephropathy by considerably boosting patients' renal 
      function, successfully lowering the inflammatory response, and producing a good 
      safety profile.
CI  - Copyright (c) 2023 Lili Yuan et al.
FAU - Yuan, Lili
AU  - Yuan L
AUID- ORCID: 0000-0001-6595-3775
AD  - Department of Nephrology, Yantai Penglai Traditional Chinese Medical Hospital, 
      Yantai, China.
FAU - Cai, Kan
AU  - Cai K
AD  - Department of Nephrology, Yantai Penglai Traditional Chinese Medical Hospital, 
      Yantai, China.
FAU - Zou, Yueji
AU  - Zou Y
AD  - Department of Radiology, Yantai Penglai Traditional Chinese Medical Hospital, 
      Yantai, China.
LA  - eng
PT  - Journal Article
DEP - 20230221
PL  - United States
TA  - Evid Based Complement Alternat Med
JT  - Evidence-based complementary and alternative medicine : eCAM
JID - 101215021
PMC - PMC9974270
COIS- The author declares that they have no conflicts of interest.
EDAT- 2023/03/04 06:00
MHDA- 2023/03/04 06:01
PMCR- 2023/02/21
CRDT- 2023/03/03 02:35
PHST- 2022/06/22 00:00 [received]
PHST- 2022/07/24 00:00 [revised]
PHST- 2022/08/14 00:00 [accepted]
PHST- 2023/03/03 02:35 [entrez]
PHST- 2023/03/04 06:00 [pubmed]
PHST- 2023/03/04 06:01 [medline]
PHST- 2023/02/21 00:00 [pmc-release]
AID - 10.1155/2023/3020033 [doi]
PST - epublish
SO  - Evid Based Complement Alternat Med. 2023 Feb 21;2023:3020033. doi: 
      10.1155/2023/3020033. eCollection 2023.